Maxipharma SRL
The score of Maxipharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +24 % Total assets +24 %
Accounts of the company itself (not consolidated).
The full file covers 20 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Maxipharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 89,731 € | ||||
| Equity | 227,467 € | ||||
| Cash | 267,253 € | ||||
| EBITDA | 127,290 € | ||||
| Total assets | 269,211 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Aug 2026
- Year ended 31 Dec 2024filed on 28 Aug 2025
- Year ended 31 Dec 2023filed on 29 Aug 2024
- Year ended 31 Dec 2022filed on 29 Aug 2023
- Year ended 31 Dec 2021filed on 25 Aug 2022
Maxipharma's financial analysis
- Solvency84.5%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Maxipharma
Maxipharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0460.509.874
- VAT number
- BE0460509874
- Peppol
- Registered · 0208:0460509874 · as of 07 Nov 2026
- Legal form
- SRL
- Incorporated
- 21 Apr 1997
- Registered office
- 6000 Charleroi
- Latest accounts
- 2025 · filed on 30 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Maxipharma (SRL) has been based in Charleroi since 1997, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 89,731 € and equity of 227,467 €; its revenue is not published. Its solvency stands at 84.5%, above the median of its sector (41.5%).
Companies similar to Maxipharma
Companies in the same business, of comparable size and area, outside its group.
- Pharm.Assy Retail sale of pharmaceutical products Wemmel · balance sheet 268,957 €
- De Baere OLV Retail sale of pharmaceutical products Roosdaal · balance sheet 269,784 €
- Apotheek Haegemans - Mertens Retail sale of pharmaceutical products Herent · balance sheet 268,422 €
- Pharmacie Boden Retail sale of pharmaceutical products Seraing · balance sheet 267,278 €
- Tripharma Retail sale of pharmaceutical products Molenbeek-Saint-Jean · balance sheet 266,344 €
- Gezondheidscentrum Vlierbeek Retail sale of pharmaceutical products Holsbeek · balance sheet 273,099 €
- Pharmacy Ghent Retail sale of pharmaceutical products Ghent · balance sheet 273,292 €
- Apoteek Brichau Retail sale of pharmaceutical products Halle · balance sheet 263,690 €
Frequently asked questions about Maxipharma
What is the revenue of Maxipharma?
Maxipharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Maxipharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0460509874 for Maxipharma, if the company is VAT-registered. Its company number (CBE) is 0460.509.874.
Where is the registered office of Maxipharma?
According to the CBE register, the registered office of Maxipharma is in 6000 Charleroi.
What is the equity of Maxipharma?
At the close of the 2025 financial year, the equity of Maxipharma amounts to 227,467 €, a solvency of 84.5% of total assets.
Who manages Maxipharma?
The register lists 1 active mandates at Maxipharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Maxipharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →